K. Tamaki

Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

N. Araya, Y. Yamano, Y. Hasegawa, 2019, Front. Microbiol..

Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity

E. Inoue, N. Araya, A. Takata, 2018, Front. Microbiol..

Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)

N. Araya, M. Nakagawa, M. Bland, 2022, Viruses.

Analysis of Immunological Factors in Platelet Transfusion-Refractory Patients-Compatible Platelets to Improve Transfusion Efficacy

S. Saito, S. Ota, K. Tamaki, 2005 .

Analysis of an Hla-B Mosaicism Observed in Apheresis Donor

S. Saito, S. Ota, K. Tamaki, 2005 .

Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis

J. Kira, H. Yonezawa, Takahiko Ueno, 2020, Orphanet Journal of Rare Diseases.

A refractory human T-cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patient with lymphoma-type adult T-cell leukemia/lymphoma

Y. Yamano, Y. Takamatsu, M. Goto, 2021, Medicine.